Gene · 8317
NIH grants1,079
NIH grants whose papers are about the gene, through NIH's grant-paper links.
321 to 340 of 1,079
Download this page as JSON| Grant | Title | CDC7 papers | Newest fiscal year |
|---|---|---|---|
| UL1TR002553 | Duke CTSA | 1 | 2023 |
| ZIABC011054 | Nuclear Factor-kappaB in Ovarian Cancer | 1 | 2023 |
| ZICDK071001 | Genomics Core Facility | 1 | 2023 |
| R01NS064131 | Developing Neuroprotective Strategies for Tau and TDP-43 Proteinopathy in FTLD | 6 | 2022 |
| I01BX004044 | Investigating calcineurin regulation of pathological TDP-43 phosphorylation in ALS | 3 | 2022 |
| R00CA207871 | Algorithms to link signaling pathways with transcriptional programs for precision medicine | 3 | 2022 |
| F30CA239335 | Defining the stromal landscape that sustains AML drug resistance | 2 | 2022 |
| R01CA093606 | Regulation of EBV Latency by EBNA1 | 2 | 2022 |
| R01CA218132 | Proteolytic control of DNA interstrand cross-link repair and genome integrity | 2 | 2022 |
| R25GM060507 | LLU-NIH Initiative for Maximizing Student Development | 2 | 2022 |
| F31AI157884 | Defining a common mechanism of SAMHD1 function in cancer, HIV, and AGS | 1 | 2022 |
| I01BX004036 | Novel mechanisms of resistance to antiandrogen therapies | 1 | 2022 |
| K08CA222676 | Functional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC) | 1 | 2022 |
| K22CA241113 | Characterizing and targeting intra-tumor heterogeneity in triple negative breast cancer chemoresistance and multi-organ metastasis | 1 | 2022 |
| R00CA241110 | Senescence-Associated Secretory Phenotype (SASP) modulation of the tumor microenvironment as a therapeutic strategy for KRAS-driven tumors | 1 | 2022 |
| R01AI097012 | Mode of action of a new Tat HIV-1 inhibitor | 1 | 2022 |
| R01AI137275 | DETERMINING THE ROLE OF THE REPLICATIVE HELICASE IN HUMAN NK CELL DEVELOPMENT | 1 | 2022 |
| R01AI165137 | Host factors regulating HIV latency and reactivation | 1 | 2022 |
| R01AR050026 | Inflammation and Cardiovascular Disease in Rheumatoid Arthritis | 1 | 2022 |
| R01CA217183 | UFM1 signaling in DNA damage response and cancer therapy | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8317/grants?page=17